Experience With a Vancomycin-sparing Empiric Antibiotic Guideline for Late-onset Sepsis in a Level-4 Neonatal...

Area of Science:

• Neonatal Medicine
• Infectious Disease Management
• Antibiotic Stewardship

Background:

• Late-onset sepsis is a common complication in neonatal intensive care units.
• Vancomycin is frequently used for suspected sepsis, raising concerns about antibiotic resistance.
• Developing targeted guidelines is crucial for optimizing antibiotic use in neonates.

Purpose of the Study:

• To evaluate the impact of a vancomycin-sparing guideline on antibiotic usage in a level-4 neonatal intensive care unit.
• To assess the effectiveness of the guideline in reducing vancomycin administration for suspected late-onset sepsis.
• To analyze the potential benefits and risks associated with the implementation of the guideline.

Main Methods:

• Implementation of a vancomycin-sparing guideline for suspected late-onset sepsis.
• Retrospective analysis of vancomycin usage patterns before and after guideline implementation.
• Monitoring of infection rates, including methicillin-resistant Staphylococcus aureus (MRSA).

Main Results:

• Significant reduction in overall vancomycin use was observed following guideline implementation.
• The guideline facilitated a decrease in vancomycin administration for suspected late-onset sepsis.
• Potential downstream beneficial effects on the unit-wide antibiotic resistance profile are suggested.

Conclusions:

• A vancomycin-sparing guideline can effectively reduce vancomycin usage in neonatal intensive care units.
• The reduction in vancomycin use may offer unit-wide benefits by mitigating antibiotic resistance.
• Careful consideration of the rare risk of methicillin-resistant Staphylococcus aureus and delayed treatment is necessary when implementing such guidelines.